Carmol Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 13 Year, 10 Months
- Last Filing with ROC 31 Mar 2021
- Revenue Growth %
- Profit Growth -2.82%
- Ebitda -2.82%
- Net Worth -30.36%
- Total Assets 264.91%
About Carmol Drugs
Carmol Drugs Private Limited (CDPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 March 2011 and has a history of 13 years and ten months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Srinivasa Reddy, Simhadri Srinivasareddy, Jaya Nalla, and One other member serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232TG2011PTC073378
-
Company No.
073378
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
18 Mar 2011
-
Date of AGM
30 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Carmol Drugs?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Srinivasa Reddy
|
Director | 18-Mar-2011 | Current |
|
Simhadri Srinivasareddy
|
Director | 28-Mar-2011 | Current |
|
Jaya Nalla
|
Additional Director | 09-Oct-2014 | Current |
|
Madhusudhana Reddy
|
Director | 29-Dec-2018 | Current |
Financial Performance of Carmol Drugs.
Carmol Drugs Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 2.82% decrease in profit. The company's net worth observed a substantial decline by a decrease of 30.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Carmol Drugs?
In 2021, Carmol Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Nalkem Pharma Private LimitedJaya Nalla is a mutual person
-
Nalkem Pharmaceuticals India Private Limited
Jaya Nalla is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Carmol Drugs?
Unlock and access historical data on people associated with Carmol Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Carmol Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Carmol Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
